Evidence map›Paper›PMID 29152128›Full record

ArticleOncotarget2017

Modulation of cabozantinib efficacy by the prostate tumor microenvironment.

Manisha Tripathi, Srinivas Nandana, Sandrine Billet, Karen A Cavassani, Rajeev Mishra, Leland W K Chung, Edwin M Posadas, Neil A Bhowmick

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Manisha Tripathi *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Srinivas Nandana *Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Sandrine BilletDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Karen A CavassaniDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Rajeev MishraDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Leland W K ChungDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Edwin M PosadasDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Neil A BhowmickDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Cedars-Sinai Medical Center · US

Funding

Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor GrowthU01CA143057 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI BHOWMICK, NEIL A., GUISE, THERESA A · 2011 to 2015
$2.7M
Paracrine Mechanisms of Prostate Cancer Metastatic ProgressionI01BX001040 · VA · VETERANS HEALTH ADMINISTRATION · PI BHOWMICK, NEIL A. · 2013 to 2020
–
BLRD VA I01 BX001040NCI NIH HHS U01 CA143057
6 · The paper itself

Abstract

The tumor microenvironment (TME) is increasingly recognized as the arbiter of metastatic progression and drug resistance in advanced prostate cancer (PCa). Cabozantinib is a potent tyrosine kinase inhibitor (TKI) with reported biological activity in the PCa epithelia, but failed to provide an overall survival benefit in phase 3 clinical trials. However, the promising biologic efficacy of the drug in early trials warranted a better understanding of the mechanism of action, with the goal of improving patient selection for TKI-based therapy such as cabozantinib. We found a 100-fold lower cabozantinib IC

Indexed as

cabozantinibcarcinoma associated fibroblastsmetastasisprostate cancer

Identifiers

PMID29152128
PMCPMC5675680
OpenAlexW2760071114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.